Compare the effectiveness and safety of drug-eluting stent (DES) vs bare metal stent (BMS) in diabetic patients treated by percutaneous coronary intervention (PCI) for short lesions in large vessels (stent diameter ≥3.0mm AND stent length ≤18mm).

Consecutive patients treated with at least one large (≥3.0mm) and short (≤18mm) stent were included over one year. Clinical and angiographic data were prospectively entered into the “Middle-Care” database and outcomes obtained at one year. We compare the occurrence of 1) cardiovascular (CV) death, 2) MACCE (CV death, Myocardial Infarction (MI) and stroke), 3) TVF (CV death, Target vessel MI, Target Vessel Revascularization (TVR)), 4) TVR and 5) Target Lesion Revascularization (TLR) as 6) Stent Thrombosis (ST) in the diabetic population according to the type of stent used (DES vs BMS).

Three hundred ninety nine patients fulfilled inclusion criteria. Among the 108 (27%) diabetic patients, 58% (n = 63) underwent PCI with BMS and 42% (n = 45) with DES. Mean age was 65±11 years, 82% (n = 89) were male, 32% (n = 35) had acute coronary syndrome, 16% acute MI. Clinical characteristics were well matched between the two groups, except for prior PCI, acute MI and multivessel disease (19% vs 49%, 24% vs 4% and 49% vs 73%, for BMS vs DES respectively, p<0.05 for all). One year follow-up was completed for 100% of the patients. Four (3.7%) patients died from CV cause, 8 (7.4%) had MACCE, 14 (13.0%) had TVF. Event rates in diabetics were similar whatever the stent used (Figure). TVF rates were similar in diabetic and non diabetic patients.

Diabetes does not increase the risk of TVF after PCI with short stents in large vessels. At one year, no additional benefit was found with the use of DES among diabetic patients in this setting.